Single polypeptide chain binding molecules
January 19, 2009. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesKeyboard operated apparatus for simultaneous coding and display of chemical structure and similar graphical information Processor for a graphic terminal Antibody fragment compositions and process Method and apparatus for making correlations and predictions using a finite field of data of unorganized and/or partially structured elements Monoclonal antibodies specific for the human transferrin receptor glycoprotein Bispecific antibody determinants Immunoglobulin half-molecules and process for producing hybrid antibodies Immunoglobulin half-molecules and process for producing hybrid antibodies Hybrid DNA prepared binding composition Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides InventorsAssigneeApplicationNo. 299617 filed on 01/19/1989US Classes:435/69.6, Blood proteins435/69.1, Recombinant DNA technique included in method of making a protein or polypeptide435/69.7, Fusion proteins or polypeptides435/252.31, Bacillus (e.g., B. subtilis, B. thuringiensis, etc.)435/252.33, Escherichia (e.g., E. coli, etc.)435/254.11, Transformants435/254.2, Yeast; media therefor435/320.1, VECTOR, PER SE (E.G., PLASMID, HYBRID PLASMID, COSMID, VIRAL VECTOR, BACTERIOPHAGE VECTOR, ETC.) BACTERIOPHAGE VECTOR, ETC.)435/361, Expressing recombinant receptor435/364, Monkey kidney435/372.1, Myeloma origin or derivative530/387.3, Chimeric, mutated, or recombined hybrid (e.g., bifunctional, bispecific, rodent-human chimeric, single chain, rFv, immunoglobulin fusion protein, etc.)530/388.24, Binds hormone or other secreted growth regulatory factor, differentiation factor, intercellular mediator, or neurotransmitter (e.g., insulin, human chorionic gonadotropin, intragonadal regulatory protein, Mullerian inhibiting substance, inhibin, epidermal growth factor, nerve growth factor, dopamine, norepinephrine, etc.)530/388.9, Binds drug, hapten, hapten--carrier complex, or specifically-identified chemical structure (e.g., theophylline, digoxin, etc.)530/861, INVOLVING IGG3, IGG4, IGA, OR IGY530/866, INVOLVING IMMUNOGLOBULIN OR ANTIBODY FRAGMENT, (E.G., F(AB)'2, FAB', FAB, FV, FC, HEAVY CHAIN, LIGHT CHAIN, ETC.)530/867, INVOLVING IMMUNOGLOBULIN OR ANTIBODY PRODUCED VIA RECOMBINANT DNA TECHNOLOGY536/23.4, Encodes a fusion protein536/24.2Non-coding sequences having no known regulatory function which are adaptors or linkers for vector or gene contructionExaminersPrimary: Teskin, Robin L.Assistant: Marks, Michelle S. Attorney, Agent or FirmForeign Patent References
International ClassesC12N 015/00C12N 015/11 C12N 015/03 C12P 021/00 696 69.7 AbstractThe invention pertains to a single polypeptide chain binding molecule which has binding specificity and affinity substantially similar to the binding specificity and affinity of the light and heavy chain aggregate variable region of an antibody, to genetic sequences coding therefor, and to recombinant DNA methods of producing such molecule and uses for such molecule.Other References
|
| ||||||||||||||
